OCULAR THERAPEUTIX, INC
Company Stats
- Market Cap
- $1.7B
- as of Sep 30, 2026
- Shares Outstanding
- 219.6M
- Free Float
- 94.4%
Income Statement
- Revenue
- $52.0M
- Operating Income
- -$270.0M
- Net Income
- -$265.9M
- EBITDA
- -$265.7M
- Revenue Growth, 3Y
- 0.3%
- FCF Margin, 3Y Avg
- -253.8%
- FCF Margin, Worst Year
- -417.5%
Cash Flow
- Free Cash Flow
- -$216.9M
- FCF Yield
- -12.9%
- Owner FCF Yield
- -15.4%
Balance Sheet
- Cash & Equivalents
- $737.1M
Returns & Capital
- SBC, 3Y Avg
- $31.4M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $52.0M | -$216.9M | -417.5% |
| FY2024 | $63.7M | -$136.0M | -213.4% |
| FY2023 | $58.4M | -$76.3M | -130.6% |
| FY2022 | $51.5M | -$63.3M | -123.0% |
| FY2021 | $43.5M | -$66.7M | -153.4% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back